Bell2Bell’s latest podcast features Josh Bartch, Co-Founder, Chairman and CEO of Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction.

Throughout the interview, Bartch discussed Mydecine’s business model, highlighting its phased approach to developing improved treatment options for a variety of underserved indications.

“Mydecine Innovations Group… is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a blueprint or starting point and then making several improvements for what we call second-generation psychedelic molecules for the treatment of a number of indications,” Bartch said.

Download(Loading)